{
    "fullText": "German Edition: DOI: 10.1002/ange.201908681Biocatalysis International Edition: DOI: 10.1002/anie.201908681 S-Adenosyl Methionine Cofactor Modifications Enhance the Bio-catalytic Repertoire of Small Molecule C-Alkylation Iain J. W. McKean, Joanna C. Sadler, Anibal Cuetos, Amina Frese, Luke D. Humphreys, Gideon Grogan,* Paul A. Hoskisson,* and Glenn A. Burley* Abstract: A tandem enzymatic strategy to enhance the scope of C-alkylation of small molecules via the in situ formation of S-adenosyl methionine (SAM) cofactor analogues is described. A solvent-exposed channel present in the SAM-forming enzyme SalL tolerates 5\u2019-chloro-5\u2019-deoxyadenosine (ClDA) analogues modified at the 2-position of the adenine nucleo-base. Coupling SalL-catalyzed cofactor production with C-(m)ethyl transfer to coumarin substrates catalyzed by the methyltransferase (MTase) NovO forms C-(m)ethylated cou-marins in superior yield and greater substrate scope relative to that obtained using cofactors lacking nucleobase modifica-tions. Establishing the molecular determinants that influence C-alkylation provides the basis to develop a late-stage enzy-matic platform for the preparation of high value small molecules. Regiospecific methylation is an essential process used in nature to modulate biological function.[1, 2] From an industrial perspective, methylation of small molecules is a powerful strategy to fine-tune their physicochemical properties and enhance overall drug potency.[3] In order to fully exploit this \u201cmagic methyl effect\u201d across the pharmaceutical and bio-technology sectors,[4, 5] robust methods are required to pre-cisely methylate\u2014and indeed alkylate\u2014substrates in an environmentally benign manner.[5\u20137] Traditional synthetic approaches have typically involved using Friedel\u2013Crafts,[8] radical-based methods,[9,10] and more recently, transition-metal catalyzed activation of C(sp2)@H bonds.[11\u201313] However, obtaining regiospecificity, particularly when this is required at a late-stage in a synthetic workflow, is an enduring challenge.[3] In contrast, MTases catalyze regio-specific C-methylation of biomolecules using the SAM cofactor as the corresponding methyl donor.[14\u201317] The repertoire of C-methylation extends to small mole-cules, which opens up opportunities to tailor these enzymes as a general platform for biocatalytic C@C bond formation (Figure 1a). A representative example is NovO, which catalyzes the C-alkylation of coumarins (e.g., 1), and forms Figure 1. Biocatalytic C-alkylation using a) S-alkylated SAM analogues, a key step in the biosynthesis of novobiocin.[18\u201320] A hallmark of NovO is its substrate promiscuity (e.g., 1) and the ability to utilize S-alkylated analogues of SAM to form products such as 2 (Figure 1a).[20, 21] One limitation of this process is the need to prepare these cofactors by chemical synthesis, which is laborious, low yielding, and produces both epimers at the sulfur center.[22\u201326] Furthermore, SAM analogues are inherently unstable in buffered solution (t1/2 942 min for SAM at pH 8).[27, 28] A more step-and atom-efficient strategy is to couple cofactor formation with C-alkyl transfer.[15, 29, 30] One example of this one-pot process is the generation of cofactor analogues in situ from either ClDA or ATP and (m)ethio-nine,[15, 29\u201333] followed by C-(m)ethyl transfer catalyzed by a MTase (Figure 1b).[34] ClDA is a shelf-stable, atom-eco-nomical adenosine source for such a process catalyzed by SalL compared to ATP, which is a substrate for SAM production by methionine adenosyltransferase (MAT).[15, 27,29, 35, 36] Although in-depth knowledge of the substrate promiscu-ity of C-MTases has been garnered from structural and mutagenesis studies,[17,19, 20, 37] little is known about how the structural features of the SAM cofactor itself influences the yield and scope of C-alkylation.[14, 30] Herein, we showcase a method to address these limitations by strategic modifica-tions to SAM and S-adenosyl ethionine (SAE, Figure 1 c). An earlier structural study of SalL in complex with ClDA and methionine revealed a solvent-exposed channel into the active site.[38\u201340] To explore this in more detail, we obtained two structures of wild-type SalL with SAM and chloride (6RYZ, 1.50 c), and with ClDA alone (6RZ2, 1.77 c; Figure 2, Supporting Information, Table S1). One significant For example, using analogues 4h or 4 j formed in situ, enhanced the conversion to 5a from 17% (using SAM) to 53% (4h) and 39 % (4 j). Further enhancement was achieved using an excess of ClDA analogues (2 equiv) and l-Met (10 equiv). In this instance, the conversion of 5 to 5a improved to 85 % (4 h) and 77 % (4j) relative to 49 % when SAM was generated in situ (Figure 5). As identified in an earlier study, MTAN was added to the reaction mixture in order to degrade the SAH analogue, which inhibits NovO.[34] The 2-modified alkyne cofactor 4 i displayed comparable conversion (5a, 50%) to SAM, whereas the formation of the 2-amino-6-chloro analogue (4g) in situ did not form 5a. Figure 3. a) Formation of SAM/SAE analogues catalyzed by SalL. b) Reaction kinetics and % conversions using modified Met analogues. Substrate Tetrazole analogues 4c, 4k, and 4 l produced significantly lower amounts of 5a relative to SAM. Enhanced levels of C-ethylation of 5 were also observed, producing 5 b from 4n (39 %) and 4o (25 %) relative to only 24% when SAE was used. Exploration of the wider scope of methylating (5 a-13a) and ethylating (5b\u201313 b) a suite of 3-substituted coumarins (5\u2013 13) exemplified the superiority of using nucle-obase-modified SAM/SAE analogues (Figure 6).[34] In almost all examples, the 2-amino-and 2-chloro-modified cofactors out-performed SAM in methylating 5\u201313. One exception was triazole 11, in which no C-(m)ethylation was observed using any of the cofactors tested. Finally, the ability of our tandem enzymatic process to (m)ethylate coumarin scaffolds with known biological activity and clinical relevance was explored. The core of coumarin 12 a is a precursor to a known inhibitor of Hsp90,[41] and is being pursued as an anti-cancer ther-apy,[42] whilst 13a is a metabolite of warfarin.[43] C-methylation was almost quantitative, produc-ing 12a (95 % conversion; 23 % isolated yield) and 13 a (92 %) when 4j was used compared to only 15 % (12a) and 7% (13 a) conversion using SAM. Ethylation of both substrates produced 12b and 13 b in 21% and 37 %, respectively. In contrast, 12b was formed in only trace amounts (3%), whereas no ethylated product (13b) was formed using SAE. In summary, we have established a new biocatalytic strategy that enhances the yield and substrate scope of small molecule C-(m)ethylation by incorporating nucleobase modi-fications within the SAM cofactor. Key to the success of this approach is the compatibility of SalL and NovO to couple in situ generation of SAM/SAE cofactor analogues (SalL) with C-(m)ethyl transfer (NovO). We envisage that blending directed evolution strategies with cofactor analogue mapping, and new strategies to recycle the SAH product formed by C-alkylation[15, 44] will provide new opportunities to identify enzyme variants with wider substrate promiscuity. Acknowledgements I.J.W.M and G.A.B. thank the Biotechnology and Biological Sciences Research Council (BBSRC) for funding (BB/ M016366/1; BB/N016378/1). J.C.S. thanks GlaxoSmithKline (GSK) and the University of Strathclyde for an industrial PhD studentship. A.C. was funded by the BBSRC (BB/ P005578/1). A.F. was funded by a studentship from GSK. We thank Dr. Johan Turkenburg and Mr. Sam Hart for assistance with X-ray data collection and the Diamond Light Source for access to beamlines (mx-9948). Finally, we thank Dr. Allan J.B. Watson for his suggestion to explore warfarin as a NovO substrate. Figure 4. Crystal structure of NovO in complex with SAH highlighting the 2-position of Conflict of interest The authors declare no conflict of interest. Keywords: alkylation \u00b7 biocatalysis \u00b7 coumarin \u00b7 methyltransferase \u00b7 S-adenosylmethionine How to cite: Angew. Chem. Int. Ed. 2019, 58, 17583\u201317588 Angew. Chem. 2019, 131, 17747\u201317752 [1] L. D. Moore, T. Le, G. Fan, Neuropsychopharmacology 2013, 38, 23. Figure 6. Substrate scope of C-(m)ethylation of coumarins 6\u201313. ClDA/ClDA analogue (400 mm), l-Met/l-ethionine (2.00 mm), coumarin [2] E. M. Harcourt, A. M. Kietrys, E. T. Kool, Nature 2017, 541, 339. [3] T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, Chem. Soc. Rev. 2016, 45, 546 \u2013 576. [4] A.-W. Struck, M. L. Thompson, L. S. Wong, J. Micklefield, ChemBioChem 2012, 13, 2642 \u2013 2655. [5] H. Sch\u00e7nherr, T. Cernak, Angew. Chem. Int. Ed. 2013, 52, 12256 \u2013 12267; Angew. Chem. 2013, 125, 12480 \u2013 12492. [6] Y. Chen, Chem. Eur. J. 2019, 25, 3405 \u2013 3439. [7] J. Bostr\u00e7m, D. G. Brown, R. J. Young, G. M. Keserg, Nat. Rev. Drug Discovery 2018, 17, 709. [8] M. Rueping, B. J. Nachtsheim, Beilstein J. Org. Chem. 2010, 6, 6. [9] J. Gui, Q. Zhou, C.-M. Pan, Y. Yabe, A. C. Burns, M. R. Collins, M. A. Ornelas, Y. Ishihara, P. S. Baran, J. Am. Chem. Soc. 2014, 136, 4853 \u2013 4856. [10] Q. Huang, S. Z. Zard, Org. Lett. 2018, 20, 1413 \u2013 1416. [11] X. Chen, K. M. Engle, D.-H. Wang, J.-Q. Yu, Angew. Chem. Int. Ed. 2009, 48, 5094 \u2013 5115; Angew. Chem. 2009, 121, 5196 \u2013 5217. [12] J. Li, K. Korvorapun, S. De Sarkar, T. Rogge, D. J. Burns, S. Warratz, L. Ackermann, Nat. Commun. 2017, 8, 15430. [13] G. Yan, A. J. Borah, L. Wang, M. Yang, Adv. Synth. Catal. 2015, 357, 1333 \u2013 1350. [14] M. R. Bennett, S. A. Shepherd, V. A. Cronin, J. Micklefield, Curr. Opin. Chem. Biol. 2017, 37, 97 \u2013 106. [15] S. Mordhorst, J. Siegrist, M. Mgller, M. Richter, J. N. Andexer, Angew. Chem. Int. Ed. 2017, 56, 4037 \u2013 4041; Angew. Chem. 2017, 129, 4095 \u2013 4099. [16] M. Tomkuviene\u0307, M. Mickute\u0307, G. Vilkaitis, S. Klimas\u030causkas, Curr. Opin. Biotechnol. 2019, 55, 114 \u2013 123. [17] T. Pavkov-Keller, K. Steiner, M. Faber, M. Tengg, H. Schwab, M. Gruber-Khadjawi, K. Gruber, PLoS One 2017, 12, e0171056. [18] J. C. Sadler, C.-w. H. Chung, J. E. Mosley, G. A. Burley, L. D. Humphreys, ACS Chem. Biol. 2017, 12, 374 \u2013 379. [19] M. Pacholec, J. Tao, C. T. Walsh, Biochemistry 2005, 44, 14969 \u2013 14976. [20] H. Stecher, M. Tengg, B. J. Ueberbacher, P. Remler, H. Schwab, H. Griengl, M. Gruber-Khadjawi, Angew. Chem. Int. Ed. 2009, 48, 9546 \u2013 9548; Angew. Chem. 2009, 121, 9710 \u2013 9712. [21] M. Tengg, H. Stecher, L. Offner, K. Plasch, F. Anderl, H. Weber, H. Schwab, M. Gruber-Khadjawi, ChemCatChem 2016, 8, 1354 \u2013 1360. [22] G. Lukinavic\u030cius, V. Lapiene\u0307, Z. Stas\u030cevskij, C. Dalhoff, E. Weinhold, S. Klimas\u030causkas, J. Am. Chem. Soc. 2007, 129, 2758 \u2013 2759. [23] J. Zhang, Y. G. Zheng, ACS Chem. Biol. 2016, 11, 583 \u2013 597. [24] K. Islam, Y. Chen, H. Wu, I. R. Bothwell, G. J. Blum, H. Zeng, A. Dong, W. Zheng, J. Min, H. Deng, M. Luo, Proc. Natl. Acad. Sci. USA 2013, 110, 16778 \u2013 16783. [25] W. Peters, S. Willnow, M. Duisken, H. Kleine, T. Macherey, K. E. Duncan, D. W. Litchfield, B. Lgscher, E. Weinhold, Angew. Chem. Int. Ed. 2010, 49, 5170 \u2013 5173; Angew. Chem. 2010, 122, 5296 \u2013 5299. [26] C. Dalhoff, G. Lukinavic\u030cius, S. Klimas\u030causkas, E. Weinhold, Nat. Chem. Biol. 2005, 2, 31. [27] T. D. Huber, F. Wang, S. Singh, B. R. Johnson, J. Zhang, M. Sunkara, S. G. Van Lanen, A. J. Morris, G. N. Phillips, J. S. Thorson, ACS Chem. Biol. 2016, 11, 2484 \u2013 2491. [28] T. D. Huber, B. R. Johnson, J. Zhang, J. S. Thorson, Curr. Opin. Biotechnol. 2016, 42, 189 \u2013 197. [29] J. M. Lipson, M. Thomsen, B. S. Moore, R. P. Clausen, J. J. La Clair, M. D. Burkart, ChemBioChem 2013, 14, 950 \u2013 953. [30] C. Vranken, A. Fin, P. Tufar, J. Hofkens, M. D. Burkart, Y. Tor, Org. Biomol. Chem. 2016, 14, 6189 \u2013 6192. [31] A. S. Eust#quio, F. Pojer, J. P. Noel, B. S. Moore, Nat. Chem. Biol. 2007, 4, 69. [32] F. Muttach, A. Rentmeister, Angew. Chem. Int. Ed. 2016, 55, 1917 \u2013 1920; Angew. Chem. 2016, 128, 1951 \u2013 1954. [33] B. J. C. Law, A.-W. Struck, M. R. Bennett, B. Wilkinson, J. Micklefield, Chem. Sci. 2015, 6, 2885 \u2013 2892. [34] J. C. Sadler, L. D. Humphreys, R. Snajdrova, G. A. Burley, ChemBioChem 2017, 18, 992 \u2013 995. [35] S. Singh, J. Zhang, T. D. Huber, M. Sunkara, K. Hurley, R. D. Goff, G. Wang, W. Zhang, C. Liu, J. Rohr, S. G. Van Lanen, A. J. Morris, J. S. Thorson, Angew. Chem. Int. Ed. 2014, 53, 3965 \u2013 3969; Angew. Chem. 2014, 126, 4046 \u2013 4050. [36] B. J. C. Law, M. R. Bennett, M. L. Thompson, C. Levi, S. A. Shepherd, D. Leys, J. Micklefield, Angew. Chem. Int. Ed. 2016, 55, 2683 \u2013 2687; Angew. Chem. 2016, 128, 2733 \u2013 2737. [37] A. Gutmann, M. Schiller, M. Gruber-Khadjawi, B. Nidetzky, Org. Biomol. Chem. 2017, 15, 7917 \u2013 7924. [38] W. L. Yeo, X. Chew, D. J. Smith, K. P. Chan, H. Sun, H. Zhao, Y. H. Lim, E. L. Ang, Chem. Commun. 2017, 53, 2559 \u2013 2562. [39] S. Thompson, S. A. McMahon, J. H. Naismith, D. OQHagan, Bioorg. Chem. 2016, 64, 37 \u2013 41. [40] S. Thompson, Q. Zhang, M. Onega, S. McMahon, I. Fleming, S. Ashworth, J. H. Naismith, J. Passchier, D. OQHagan, Angew. Chem. Int. Ed. 2014, 53, 8913 \u2013 8918; Angew. Chem. 2014, 126, 9059 \u2013 9064. [41] X. M. Yu, G. Shen, L. Neckers, H. Blake, J. Holzbeierlein, B. Cronk, B. S. J. Blagg, J. Am. Chem. Soc. 2005, 127, 12778 \u2013 12779. [42] J. Zhao, H. Zhao, J. A. Hall, D. Brown, E. Brandes, J. Bazzill, P. T. Grogan, C. Subramanian, G. Vielhauer, M. S. Cohen, B. S. J. Blagg, MedChemComm 2014, 5, 1317 \u2013 1323. [43] A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, W. F. Trager, Chem. Res. Toxicol. 1992, 5, 54 \u2013 59. [44] C. Liao, F. P. Seebeck, Nat. Catal. 2019, 2, 696 \u2013 701. Manuscript received: July 12, 2019 Revised manuscript received: September 11, 2019 Accepted manuscript online: October 1, 2019 Version of record online: October 21, 2019 Angewandte ChemieCommunications 17588 www.angewandte.org T 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2019, 58, 17583 \u201317588",
    "content": [
        "German Edition: DOI: 10.1002/ange.201908681Biocatalysis International Edition: DOI: 10.1002/anie.201908681",
        "S-Adenosyl Methionine Cofactor Modifications Enhance the Bio-catalytic Repertoire of Small Molecule C-Alkylation",
        "Iain J. W. McKean, Joanna C. Sadler, Anibal Cuetos, Amina Frese, Luke D. Humphreys, Gideon Grogan,* Paul A. Hoskisson,* and Glenn A. Burley*",
        "Abstract: A tandem enzymatic strategy to enhance the scope of C-alkylation of small molecules via the in situ formation of S-adenosyl methionine (SAM) cofactor analogues is described. A solvent-exposed channel present in the SAM-forming enzyme SalL tolerates 5\u2019-chloro-5\u2019-deoxyadenosine (ClDA) analogues modified at the 2-position of the adenine nucleo-base. Coupling SalL-catalyzed cofactor production with C-(m)ethyl transfer to coumarin substrates catalyzed by the methyltransferase (MTase) NovO forms C-(m)ethylated cou-marins in superior yield and greater substrate scope relative to that obtained using cofactors lacking nucleobase modifica-tions. Establishing the molecular determinants that influence C-alkylation provides the basis to develop a late-stage enzy-matic platform for the preparation of high value small molecules.",
        "Regiospecific methylation is an essential process used in nature to modulate biological function.[1, 2] From an industrial perspective, methylation of small molecules is a powerful strategy to fine-tune their physicochemical properties and enhance overall drug potency.[3] In order to fully exploit this \u201cmagic methyl effect\u201d across the pharmaceutical and bio-technology sectors,[4, 5] robust methods are required to pre-cisely methylate\u2014and indeed alkylate\u2014substrates in an environmentally benign manner.[5\u20137]",
        "Traditional synthetic approaches have typically involved using Friedel\u2013Crafts,[8] radical-based methods,[9,10] and more recently, transition-metal catalyzed activation of C(sp2)@H bonds.[11\u201313] However, obtaining regiospecificity, particularly when this is required at a late-stage in a synthetic workflow, is an enduring challenge.[3] In contrast, MTases catalyze regio-specific C-methylation of biomolecules using the SAM cofactor as the corresponding methyl donor.[14\u201317]",
        "The repertoire of C-methylation extends to small mole-cules, which opens up opportunities to tailor these enzymes as a general platform for biocatalytic C@C bond formation (Figure 1a). A representative example is NovO, which catalyzes the C-alkylation of coumarins (e.g., 1), and forms",
        "Figure 1. Biocatalytic C-alkylation using a) S-alkylated SAM analogues,",
        "a key step in the biosynthesis of novobiocin.[18\u201320] A hallmark of NovO is its substrate promiscuity (e.g., 1) and the ability to utilize S-alkylated analogues of SAM to form products such as 2 (Figure 1a).[20, 21]",
        "One limitation of this process is the need to prepare these cofactors by chemical synthesis, which is laborious, low yielding, and produces both epimers at the sulfur center.[22\u201326] Furthermore, SAM analogues are inherently unstable in buffered solution (t1/2 942 min for SAM at pH 8).[27, 28] A more step-and atom-efficient strategy is to couple cofactor formation with C-alkyl transfer.[15, 29, 30] One example of this one-pot process is the generation of cofactor analogues in situ from either ClDA or ATP and (m)ethio-nine,[15, 29\u201333] followed by C-(m)ethyl transfer catalyzed by a MTase (Figure 1b).[34] ClDA is a shelf-stable, atom-eco-nomical adenosine source for such a process catalyzed by SalL compared to ATP, which is a substrate for SAM production by methionine adenosyltransferase (MAT).[15, 27,29, 35, 36]",
        "Although in-depth knowledge of the substrate promiscu-ity of C-MTases has been garnered from structural and mutagenesis studies,[17,19, 20, 37] little is known about how the structural features of the SAM cofactor itself influences the yield and scope of C-alkylation.[14, 30] Herein, we showcase a method to address these limitations by strategic modifica-tions to SAM and S-adenosyl ethionine (SAE, Figure 1 c).",
        "An earlier structural study of SalL in complex with ClDA and methionine revealed a solvent-exposed channel into the active site.[38\u201340] To explore this in more detail, we obtained two structures of wild-type SalL with SAM and chloride (6RYZ, 1.50 c), and with ClDA alone (6RZ2, 1.77 c; Figure 2, Supporting Information, Table S1). One significant",
        "For example, using analogues 4h or 4 j formed in situ, enhanced the conversion to 5a from 17% (using SAM) to 53% (4h) and 39 % (4 j). Further enhancement was achieved using an excess of ClDA analogues (2 equiv) and l-Met (10 equiv). In this instance, the conversion of 5 to 5a improved to 85 % (4 h) and 77 % (4j) relative to 49 % when SAM was generated in situ (Figure 5). As identified in an earlier study, MTAN was added to the reaction mixture in order to degrade the SAH analogue, which inhibits NovO.[34] The 2-modified alkyne cofactor 4 i displayed comparable conversion (5a, 50%) to SAM, whereas the formation of the 2-amino-6-chloro analogue (4g) in situ did not form 5a.",
        "Figure 3. a) Formation of SAM/SAE analogues catalyzed by SalL. b) Reaction kinetics and % conversions using modified Met analogues. Substrate",
        "Tetrazole analogues 4c, 4k, and 4 l produced significantly lower amounts of 5a relative to SAM. Enhanced levels of C-ethylation of 5 were also observed, producing 5 b from 4n (39 %) and 4o (25 %) relative to only 24% when SAE was used. Exploration of the wider scope of methylating (5 a-13a) and ethylating (5b\u201313 b) a suite of 3-substituted coumarins (5\u2013 13) exemplified the superiority of using nucle-obase-modified SAM/SAE analogues (Figure 6).[34] In almost all examples, the 2-amino-and 2-chloro-modified cofactors out-performed SAM in methylating 5\u201313. One exception was triazole 11, in which no C-(m)ethylation was observed using any of the cofactors tested. Finally, the ability of our tandem enzymatic process to (m)ethylate coumarin scaffolds with known biological activity and clinical relevance was explored. The core of coumarin 12 a is a precursor to a known inhibitor of Hsp90,[41] and is being pursued as an anti-cancer ther-apy,[42] whilst 13a is a metabolite of warfarin.[43] C-methylation was almost quantitative, produc-ing 12a (95 % conversion; 23 % isolated yield) and 13 a (92 %) when 4j was used compared to only 15 % (12a) and 7% (13 a) conversion using SAM. Ethylation of both substrates produced 12b and 13 b in 21% and 37 %, respectively. In contrast, 12b was formed in only trace amounts",
        "(3%), whereas no ethylated product (13b) was formed using SAE.",
        "In summary, we have established a new biocatalytic strategy that enhances the yield and substrate scope of small molecule C-(m)ethylation by incorporating nucleobase modi-fications within the SAM cofactor. Key to the success of this approach is the compatibility of SalL and NovO to couple in situ generation of SAM/SAE cofactor analogues (SalL) with C-(m)ethyl transfer (NovO). We envisage that blending directed evolution strategies with cofactor analogue mapping, and new strategies to recycle the SAH product formed by C-alkylation[15, 44] will provide new opportunities to identify enzyme variants with wider substrate promiscuity.",
        "Acknowledgements",
        "I.J.W.M and G.A.B. thank the Biotechnology and Biological Sciences Research Council (BBSRC) for funding (BB/ M016366/1; BB/N016378/1). J.C.S. thanks GlaxoSmithKline (GSK) and the University of Strathclyde for an industrial PhD studentship. A.C. was funded by the BBSRC (BB/ P005578/1). A.F. was funded by a studentship from GSK. We thank Dr. Johan Turkenburg and Mr. Sam Hart for assistance with X-ray data collection and the Diamond Light Source for access to beamlines (mx-9948). Finally, we thank Dr. Allan J.B. Watson for his suggestion to explore warfarin as a NovO substrate.",
        "Figure 4. Crystal structure of NovO in complex with SAH highlighting the 2-position of",
        "Conflict of interest",
        "The authors declare no conflict of interest.",
        "Keywords: alkylation \u00b7 biocatalysis \u00b7 coumarin \u00b7 methyltransferase \u00b7 S-adenosylmethionine How to cite: Angew. Chem. Int. Ed. 2019, 58, 17583\u201317588",
        "Angew. Chem. 2019, 131, 17747\u201317752",
        "[1] L. D. Moore, T. Le, G. Fan, Neuropsychopharmacology 2013, 38, 23.",
        "Figure 6. Substrate scope of C-(m)ethylation of coumarins 6\u201313. ClDA/ClDA analogue (400 mm), l-Met/l-ethionine (2.00 mm), coumarin",
        "[2] E. M. Harcourt, A. M. Kietrys, E. T. Kool, Nature 2017, 541, 339. [3] T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, Chem. Soc. Rev. 2016, 45, 546 \u2013 576. [4] A.-W. Struck, M. L. Thompson, L. S. Wong, J. Micklefield, ChemBioChem 2012, 13, 2642 \u2013 2655. [5] H. Sch\u00e7nherr, T. Cernak, Angew. Chem. Int. Ed. 2013, 52, 12256 \u2013 12267; Angew. Chem. 2013, 125, 12480 \u2013 12492. [6] Y. Chen, Chem. Eur. J. 2019, 25, 3405 \u2013 3439. [7] J. Bostr\u00e7m, D. G. Brown, R. J. Young, G. M. Keserg, Nat. Rev. Drug Discovery 2018, 17, 709. [8] M. Rueping, B. J. Nachtsheim, Beilstein J. Org. Chem. 2010, 6, 6. [9] J. Gui, Q. Zhou, C.-M. Pan, Y. Yabe, A. C. Burns, M. R. Collins, M. A. Ornelas, Y. Ishihara, P. S. Baran, J. Am. Chem. Soc. 2014, 136, 4853 \u2013 4856. [10] Q. Huang, S. Z. Zard, Org. Lett. 2018, 20, 1413 \u2013 1416. [11] X. Chen, K. M. Engle, D.-H. Wang, J.-Q. Yu, Angew. Chem. Int. Ed. 2009, 48, 5094 \u2013 5115; Angew. Chem. 2009, 121, 5196 \u2013 5217. [12] J. Li, K. Korvorapun, S. De Sarkar, T. Rogge, D. J. Burns, S. Warratz, L. Ackermann, Nat. Commun. 2017, 8, 15430. [13] G. Yan, A. J. Borah, L. Wang, M. Yang, Adv. Synth. Catal. 2015, 357, 1333 \u2013 1350. [14] M. R. Bennett, S. A. Shepherd, V. A. Cronin, J. Micklefield, Curr. Opin. Chem. Biol. 2017, 37, 97 \u2013 106. [15] S. Mordhorst, J. Siegrist, M. Mgller, M. Richter, J. N. Andexer, Angew. Chem. Int. Ed. 2017, 56, 4037 \u2013 4041; Angew. Chem. 2017, 129, 4095 \u2013 4099. [16] M. Tomkuviene\u0307, M. Mickute\u0307, G. Vilkaitis, S. Klimas\u030causkas, Curr. Opin. Biotechnol. 2019, 55, 114 \u2013 123. [17] T. Pavkov-Keller, K. Steiner, M. Faber, M. Tengg, H. Schwab, M. Gruber-Khadjawi, K. Gruber, PLoS One 2017, 12, e0171056. [18] J. C. Sadler, C.-w. H. Chung, J. E. Mosley, G. A. Burley, L. D. Humphreys, ACS Chem. Biol. 2017, 12, 374 \u2013 379. [19] M. Pacholec, J. Tao, C. T. Walsh, Biochemistry 2005, 44, 14969 \u2013 14976. [20] H. Stecher, M. Tengg, B. J. Ueberbacher, P. Remler, H. Schwab, H. Griengl, M. Gruber-Khadjawi, Angew. Chem. Int. Ed. 2009, 48, 9546 \u2013 9548; Angew. Chem. 2009, 121, 9710 \u2013 9712. [21] M. Tengg, H. Stecher, L. Offner, K. Plasch, F. Anderl, H. Weber, H. Schwab, M. Gruber-Khadjawi, ChemCatChem 2016, 8, 1354 \u2013 1360. [22] G. Lukinavic\u030cius, V. Lapiene\u0307, Z. Stas\u030cevskij, C. Dalhoff, E. Weinhold, S. Klimas\u030causkas, J. Am. Chem. Soc. 2007, 129, 2758 \u2013 2759. [23] J. Zhang, Y. G. Zheng, ACS Chem. Biol. 2016, 11, 583 \u2013 597. [24] K. Islam, Y. Chen, H. Wu, I. R. Bothwell, G. J. Blum, H. Zeng, A. Dong, W. Zheng, J. Min, H. Deng, M. Luo, Proc. Natl. Acad. Sci. USA 2013, 110, 16778 \u2013 16783. [25] W. Peters, S. Willnow, M. Duisken, H. Kleine, T. Macherey, K. E. Duncan, D. W. Litchfield, B. Lgscher, E. Weinhold, Angew. Chem. Int. Ed. 2010, 49, 5170 \u2013 5173; Angew. Chem. 2010, 122, 5296 \u2013 5299.",
        "[26] C. Dalhoff, G. Lukinavic\u030cius, S. Klimas\u030causkas, E. Weinhold, Nat. Chem. Biol. 2005, 2, 31. [27] T. D. Huber, F. Wang, S. Singh, B. R. Johnson, J. Zhang, M. Sunkara, S. G. Van Lanen, A. J. Morris, G. N. Phillips, J. S. Thorson, ACS Chem. Biol. 2016, 11, 2484 \u2013 2491. [28] T. D. Huber, B. R. Johnson, J. Zhang, J. S. Thorson, Curr. Opin. Biotechnol. 2016, 42, 189 \u2013 197. [29] J. M. Lipson, M. Thomsen, B. S. Moore, R. P. Clausen, J. J. La Clair, M. D. Burkart, ChemBioChem 2013, 14, 950 \u2013 953. [30] C. Vranken, A. Fin, P. Tufar, J. Hofkens, M. D. Burkart, Y. Tor, Org. Biomol. Chem. 2016, 14, 6189 \u2013 6192. [31] A. S. Eust#quio, F. Pojer, J. P. Noel, B. S. Moore, Nat. Chem. Biol. 2007, 4, 69. [32] F. Muttach, A. Rentmeister, Angew. Chem. Int. Ed. 2016, 55, 1917 \u2013 1920; Angew. Chem. 2016, 128, 1951 \u2013 1954. [33] B. J. C. Law, A.-W. Struck, M. R. Bennett, B. Wilkinson, J. Micklefield, Chem. Sci. 2015, 6, 2885 \u2013 2892. [34] J. C. Sadler, L. D. Humphreys, R. Snajdrova, G. A. Burley, ChemBioChem 2017, 18, 992 \u2013 995. [35] S. Singh, J. Zhang, T. D. Huber, M. Sunkara, K. Hurley, R. D. Goff, G. Wang, W. Zhang, C. Liu, J. Rohr, S. G. Van Lanen, A. J. Morris, J. S. Thorson, Angew. Chem. Int. Ed. 2014, 53, 3965 \u2013 3969; Angew. Chem. 2014, 126, 4046 \u2013 4050. [36] B. J. C. Law, M. R. Bennett, M. L. Thompson, C. Levi, S. A. Shepherd, D. Leys, J. Micklefield, Angew. Chem. Int. Ed. 2016, 55, 2683 \u2013 2687; Angew. Chem. 2016, 128, 2733 \u2013 2737. [37] A. Gutmann, M. Schiller, M. Gruber-Khadjawi, B. Nidetzky, Org. Biomol. Chem. 2017, 15, 7917 \u2013 7924. [38] W. L. Yeo, X. Chew, D. J. Smith, K. P. Chan, H. Sun, H. Zhao, Y. H. Lim, E. L. Ang, Chem. Commun. 2017, 53, 2559 \u2013 2562. [39] S. Thompson, S. A. McMahon, J. H. Naismith, D. OQHagan, Bioorg. Chem. 2016, 64, 37 \u2013 41. [40] S. Thompson, Q. Zhang, M. Onega, S. McMahon, I. Fleming, S. Ashworth, J. H. Naismith, J. Passchier, D. OQHagan, Angew. Chem. Int. Ed. 2014, 53, 8913 \u2013 8918; Angew. Chem. 2014, 126, 9059 \u2013 9064. [41] X. M. Yu, G. Shen, L. Neckers, H. Blake, J. Holzbeierlein, B. Cronk, B. S. J. Blagg, J. Am. Chem. Soc. 2005, 127, 12778 \u2013 12779. [42] J. Zhao, H. Zhao, J. A. Hall, D. Brown, E. Brandes, J. Bazzill, P. T. Grogan, C. Subramanian, G. Vielhauer, M. S. Cohen, B. S. J. Blagg, MedChemComm 2014, 5, 1317 \u2013 1323. [43] A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, W. F. Trager, Chem. Res. Toxicol. 1992, 5, 54 \u2013 59. [44] C. Liao, F. P. Seebeck, Nat. Catal. 2019, 2, 696 \u2013 701.",
        "Manuscript received: July 12, 2019 Revised manuscript received: September 11, 2019 Accepted manuscript online: October 1, 2019 Version of record online: October 21, 2019",
        "Angewandte",
        "ChemieCommunications",
        "17588 www.angewandte.org T 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2019, 58, 17583 \u201317588"
    ]
}